Table 2. SURGENE cohort: Genotype frequencies of SOD2 polymorphisms by incidence of renal events during follow-up.
| Renal events | ||||
| SNP | No (n = 242) | Yes (n = 98) | HR (95% C.I.) | p |
| rs4342445 | ||||
| GG | 0.584 | 0.622 | 1.08 | 0.72 |
| GA | 0.353 | 0.347 | (0.70–1.70) | |
| AA | 0.063 | 0.031 | ||
| MAF | 0.240 | 0.204 | ||
| rs2758329 | ||||
| TT | 0.283 | 0.381 | 1.94 | 0.006 |
| TC | 0.493 | 0.392 | (1.22–3.04) | |
| CC | 0.224 | 0.227 | ||
| MAF | 0.471 | 0.423 | ||
| rs2842980 | ||||
| AA | 0.590 | 0.532 | 0.79 | 0.28 |
| AT | 0.360 | 0.372 | (0.51–1.22) | |
| TT | 0.050 | 0.096 | ||
| MAF | 0.230 | 0.282 | ||
| rs7855 | ||||
| AA | 0.874 | 0.887 | 1.03 | 0.93 |
| AG | 0.126 | 0.113 | (0.51–1.89) | |
| GG | 0 | 0 | ||
| MAF | 0.063 | 0.057 | ||
| rs8031 | ||||
| TT | 0.293 | 0.381 | 1.90 | 0.007 |
| TA | 0.482 | 0.392 | (1.19–2.98) | |
| AA | 0.225 | 0.227 | ||
| MAF | 0.466 | 0.423 | ||
| rs5746141 | ||||
| GG | 0.929 | 0.857 | 0.66 | 0.21 |
| GA | 0.067 | 0.143 | (0.36–1.30) | |
| AA | 0.004 | 0 | ||
| MAF | 0.038 | 0.071 | ||
| rs5746136 | ||||
| GG | 0.528 | 0.479 | 1.10 | 0.61 |
| GA | 0.367 | 0.469 | (0.62–1.42) | |
| AA | 0.105 | 0.052 | ||
| MAF | 0.289 | 0.286 | ||
| rs4880 | ||||
| TT | 0.295 | 0.381 | 1.99 | 0.004 |
| TC | 0.484 | 0.392 | (1.24–3.12) | |
| CC | 0.221 | 0.227 | ||
| MAF | 0.463 | 0.423 | ||
SNPs are sorted in 5′ to 3′ order. Hazards ratio for the major allele in a recessive model (MM vs Xm) determined in Cox proportional hazards survival regressive model, adjusted for sex, age, duration of diabetes, treatment by ACE inhibitors and retinopathy stages. Retinopathy was coded as an ordinal polytomic covariate: absent (1), non-proliferative (2), pre-proliferative (3), or proliferative retinopathy (4). MAF: minor allele frequency. p≤0.01 is significant.